DDS - Decision Feb 11 2010

[mesmail]

Labopharm's novel formulation of trazodone is currently under regulatory review in the U.S. with an action date under the Prescription Drug Users Fee Act (PDUFA) of February 11, 2010. Labopharm received a complete response letter from the FDA on July 17, 2009 indicating the Company's new drug application (NDA) for its novel trazodone formulation could not be approved in its present form due to the deficiencies at the API supplier's manufacturing facility. The letter did not raise any efficacy or safety issues

[ixroth99]

today feb 02 fda took action on MYRIAD (myrx) maker of pain killing drugs among them "javelin"

does anybody have any oppinion on this compny it sound interesting to me as the company has a book value of $7 and currently is trading at about $4.5 any comments are greatly appreciated
This company is for real it has 186 employees and did have sales in excess of one million